Search
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
Abiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigationalAbiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.
Plerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigationalSince CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment, blocking this interaction leads to an increase in CD34+ cell circulating levels. … [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678]
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.
Chlorothiazide
go.drugbank.com/drugs/DB00880ApprovedInvestigationalVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Icosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalFDA approved on July 26, 2012. … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.
Synonyms: E-EPACollagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. … Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum.
Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.
Scarlet red
go.drugbank.com/drugs/DB19136ApprovedWithdrawnScarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).
Categories: Compounds used in a research, industrial, or household setting